Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 1
2006 1
2009 5
2010 7
2011 5
2012 3
2013 3
2014 7
2015 8
2016 8
2017 6
2018 10
2019 7
2020 16
2021 26
2022 31
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
FINDINGS: Between June 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to receive ustekinumab (n=191) or adalimumab (n=195). 29 (15%) of 191 patients in the ustekinumab group and 46 (24%) of 195 in t …
FINDINGS: Between June 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to …
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection.
Desai JV, Kumar D, Freiwald T, Chauss D, Johnson MD, Abers MS, Steinbrink JM, Perfect JR, Alexander B, Matzaraki V, Snarr BD, Zarakas MA, Oikonomou V, Silva LM, Shivarathri R, Beltran E, Demontel LN, Wang L, Lim JK, Launder D, Conti HR, Swamydas M, McClain MT, Moutsopoulos NM, Kazemian M, Netea MG, Kumar V, Köhl J, Kemper C, Afzali B, Lionakis MS. Desai JV, et al. Cell. 2023 Jun 22;186(13):2802-2822.e22. doi: 10.1016/j.cell.2023.04.031. Epub 2023 May 22. Cell. 2023. PMID: 37220746
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells.
Chauss D, Freiwald T, McGregor R, Yan B, Wang L, Nova-Lamperti E, Kumar D, Zhang Z, Teague H, West EE, Vannella KM, Ramos-Benitez MJ, Bibby J, Kelly A, Malik A, Freeman AF, Schwartz DM, Portilla D, Chertow DS, John S, Lavender P, Kemper C, Lombardi G, Mehta NN, Cooper N, Lionakis MS, Laurence A, Kazemian M, Afzali B. Chauss D, et al. Nat Immunol. 2022 Jan;23(1):62-74. doi: 10.1038/s41590-021-01080-3. Epub 2021 Nov 11. Nat Immunol. 2022. PMID: 34764490 Free PMC article.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Sandborn WJ, et al. Gastroenterology. 2022 May;162(6):1650-1664.e8. doi: 10.1053/j.gastro.2022.01.047. Epub 2022 Feb 5. Gastroenterology. 2022. PMID: 35134323 Free article. Clinical Trial.
Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.
Break TJ, Oikonomou V, Dutzan N, Desai JV, Swidergall M, Freiwald T, Chauss D, Harrison OJ, Alejo J, Williams DW, Pittaluga S, Lee CR, Bouladoux N, Swamydas M, Hoffman KW, Greenwell-Wild T, Bruno VM, Rosen LB, Lwin W, Renteria A, Pontejo SM, Shannon JP, Myles IA, Olbrich P, Ferré EMN, Schmitt M, Martin D; Genomics and Computational Biology Core; Barber DL, Solis NV, Notarangelo LD, Serreze DV, Matsumoto M, Hickman HD, Murphy PM, Anderson MS, Lim JK, Holland SM, Filler SG, Afzali B, Belkaid Y, Moutsopoulos NM, Lionakis MS. Break TJ, et al. Science. 2021 Jan 15;371(6526):eaay5731. doi: 10.1126/science.aay5731. Science. 2021. PMID: 33446526 Free PMC article.
Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.
Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C. Liszewski MK, et al. Immunity. 2013 Dec 12;39(6):1143-57. doi: 10.1016/j.immuni.2013.10.018. Epub 2013 Dec 5. Immunity. 2013. PMID: 24315997 Free PMC article.
The state of complement in COVID-19.
Afzali B, Noris M, Lambrecht BN, Kemper C. Afzali B, et al. Nat Rev Immunol. 2022 Feb;22(2):77-84. doi: 10.1038/s41577-021-00665-1. Epub 2021 Dec 15. Nat Rev Immunol. 2022. PMID: 34912108 Free PMC article. Review.
BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells.
Yao C, Lou G, Sun HW, Zhu Z, Sun Y, Chen Z, Chauss D, Moseman EA, Cheng J, D'Antonio MA, Shi W, Shi J, Kometani K, Kurosaki T, Wherry EJ, Afzali B, Gattinoni L, Zhu Y, McGavern DB, O'Shea JJ, Schwartzberg PL, Wu T. Yao C, et al. Nat Immunol. 2021 Mar;22(3):370-380. doi: 10.1038/s41590-021-00868-7. Epub 2021 Feb 11. Nat Immunol. 2021. PMID: 33574619 Free PMC article.
Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection.
West EE, Merle NS, Kamiński MM, Palacios G, Kumar D, Wang L, Bibby JA, Overdahl K, Jarmusch AK, Freeley S, Lee DY, Thompson JW, Yu ZX, Taylor N, Sitbon M, Green DR, Bohrer A, Mayer-Barber KD, Afzali B, Kazemian M, Scholl-Buergi S, Karall D, Huemer M, Kemper C. West EE, et al. Immunity. 2023 Sep 12;56(9):2036-2053.e12. doi: 10.1016/j.immuni.2023.07.014. Epub 2023 Aug 11. Immunity. 2023. PMID: 37572656 Free PMC article.
143 results